The Novo Nordisk company, taking social responsibility and caring for patients, informs about the current situation with illegal import and trafficking of medicines such as Ozempic®, Saxenda® and Rebelsas® on the territory of the Republic of Kazakhstan.
Novo Nordisk became aware of the fact of illegal import, as well as the dissemination of false information and discrediting of the company's medicines, through social networks: Instagram and Telegram.
Novo Nordisk does not recommend purchasing medicinal products, in particular Ozempic®, manufactured for sale on the markets of other countries.
Ozempic® has special storage and transport conditions, and the company cannot guarantee the quality and safety of illegally imported preparations. By purchasing such products, you are at risk of encountering a low-quality product and bearfull responsibility for the potential safety risk.
Our company takes appropriate actions to prevent cases of illegal import of Novo Nordisk medicines:
We would like to remind you that according to the legislation: Only an official distributor licensed for the wholesale distribution of medicines, has the right to legally sell Novo Nordisk products through pharmacy chains in the territory of the Republic of Kazakhstan, subject to compliance with all transport and storage standards set by the company.
Be aware of the risk of counterfeit products and carefully check the purchased product before use.
If you find a counterfeitproduct, do not use it and contact by email firstname.lastname@example.org or by phone +7 (727) 3307788. If you have used a product that you suspect is counterfeit, contact your doctor immediately.
Patient safety is a top priority for Novo Nordisk and we are in close dialogue with all stakeholders to best support patients in the fight against counterfeit products.
If you have any questions, please contact us by email at email@example.com, or by phone at +7 (727) 3307788.
Novo Nordisk has been made aware of some Ozempic® and Saxenda® pens in Uzbekistan, Azerbaijan and Kazakhstan that have been falsified and are not legitimate. The falsified products have been sold both within the legal and illegal supply chain. The content of the falsified pens is entirely different from the genuine products and should not be used as the falsified pens pose a risk to patients’ safety.
The main difference between the counterfeit product and the genuine product is that the genuine Novo Nordisk Ozempic® and Saxenda® pens do not extend or increase in length when setting the dose. The scale drum increments are fixed doses, such as 0.25 mg, 0.5 mg, and 1.0 mg for Ozempic® and 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg for Saxenda®.
A falsified pen can be identified based on scale going from 0 to 80 units and extending out from the pen when setting the dose.
Patient safety is a top priority for Novo Nordisk and we are in close dialogue with all relevant stakeholders to support patients in the best possible way against falsified products.
If you have any questions, please contact firstname.lastname@example.org or call +7 (727) 3307788.